OBJECTIVES

Several new agents have been approved for treating R/R DLBCL recently. Loncastuximab, a single-agent therapy with 30-minute infusion, has shown substantial antitumor activity and a manageable toxicity profile in a phase II trial. This analysis was performed to project the treatment-related costs associated with loncastuximab in comparison with the newer pharmacologic treatments that were approved after 2019 in patients with R/R DLBCL who have received ≥2L of therapies.

METHODS

A model was developed to assess treatment-related costs during the treatment course for the following treatments: loncastuximab, polatuzumab + bendamustine + rituximab (pola + BR), tafasitamab + lenalidomide, and selinexor. Cost components included drug administration, premedication, monitoring, prophylactic treatments, and adverse event (AE) costs. While it was assumed that Grade 3/4 AEs were incurred only once during the treatment, other costs were incurred throughout the treatment and were estimated on a monthly basis. Model inputs were obtained from drug labels, clinical trials, public data sources (i.e., RedBook, Centers for Medicare & Medicaid Services (CMS) physician fee schedule, Healthcare Cost and Utilization Project [HCUP.net]) or literature. All costs were estimated in 2020 USD.

RESULTS

During the treatment course, loncastuximab incurred the lowest AE costs ($6,369), followed by tafasitamab + lenalidomide ($15,079), selinexor ($22,020), and pola + BR ($27,307). Loncastuximab also brought the lowest monthly cost associated with drug administration, premedication, monitoring and prophylactic treatments at $683, followed by selinexor ($1,143), tafasitamab + lenalidomide ($1,609 during the co-administration phase, and $1,414 during the monotherapy phase), and pola + BR ($2,256).

CONCLUSIONS

Compared with all the newer pharmacologic treatments indicated for R/R DLBCL, loncastuximab was associated with the lowest treatment-related costs due to its lowest AE costs and ease of administration.